Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of TS-142 in Insomnia Disorder
NCT04573725Phase 2Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vornorexant in insomnia disorder (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Latency to Persistent Sleep at Day 1 and Wake After Sleep Onset at Day 1. Started Jul 2017; status: completed.
02
Drugs
vornorexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT04573725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573725.